Injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium

Abstract

The invention provides an injection-use pharmaceutical composition comprising cefmetazole sodium and clavulanate potassium, and the pharmaceutical composition has a cooperatively antibacterial effect. The pharmaceutical composition comprises the following ingredients: in parts by weight, 1-4 parts of the cefmetazole sodium; 1-2 parts of the clavulanate potassium; 2-6 parts of polyalkylcyanoacrylate; 0.2-0.5 parts of L-arginine; 0.5-1 parts of PVP; 0.5-1 parts of mannitol; 0.5-1 parts of glycine; 1-2 parts of a tween. The pharmaceutical composition has the advantages of high stability, good redissolubility, simple preparation processes, a good inhibitory effect on ESBLs-producing escherichiacoli, klebsiellapeumoniae, and proteusmirabilis, and a definite curative effect, can reduce the dosage of a single prescription preparation and shorten the treatment cycle, and has broad market prospects.

Description

technical field [0001] The invention relates to a compound preparation of β-lactam antibiotics and β-lactamase inhibitors, in particular to a pharmaceutical composition of cefmetazole sodium and clavulanate potassium for injection. Background technique [0002] β-lactam antibiotics (β-lactams) refer to a large class of antibiotics with a β-lactam ring in their chemical structure, including the most commonly used penicillins and cephalosporins in clinical practice, as well as the newly developed cephamycins and thiomycetes. Other atypical β-lactam antibiotics such as steroids and monocyclic β-lactams. Such antibiotics have the advantages of strong bactericidal activity, low toxicity, wide indications and good clinical curative effect. The chemical structure of this class of drugs, especially the change of the side chain, has formed many antibiotics with different antibacterial spectrum and antibacterial effect and various clinical pharmacological properties. [0003] Cefmet...

AI Technical Summary

Problems solved by technology

[0005] The pharmaceutical composition of some β-lactam antibiotics and β-lactamase inhibitors has been disclosed in the prior art, but because different β-lactam antibiotics have specific antibacterial spectrum, different β-lactamase The inhibitory spectrum and stability of the inhibitors are also different, resulting in the pharmaceutical composition including β-lactam antibiotics and β-lactamase inhibitors, the degree of optimization of the antibacterial activity is not yet predictable

Moreover, different dosage ratios have a great impact on the antibacterial activity of the composition of β-lactam antibiotics and β-lactamase inhibitors, and there is no fixed rule to follow in the many teachings given by the prior art.

Images